Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 20/20 | 0.68 |
| ▸ | TACR2 | P21452 | 1/20 | 0.52 |
| ▸ | HRH2 | P25021 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3282272 | 0.90 | GNRHR (0.84) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL3274997 | 0.89 | GNRHR (0.66) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL3274234 | 0.89 | GNRHR (0.70) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL3279247 | 0.87 | GNRHR (0.72) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL3276312 | 0.86 | GNRHR (0.82) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL3274951 | 0.85 | GNRHR (0.68) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL3275103 | 0.85 | GNRHR (0.65) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL3274900 | 0.85 | GNRHR (0.65) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL3276154 | 0.85 | GNRHR (0.65) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL3276168 | 0.85 | GNRHR (0.65) | GNRHRTACR2HRH2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696210-B2 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2010-04-13 | — | — | US | claimed |
| EP-1758895-A1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2007-03-07 | — | — | EP | claimed |
| US-20060019965-A1 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2006-01-26 | — | — | US | claimed |
| WO-2006009734-A1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | WYETH (US) | 2006-01-26 | — | — | WO | claimed |
| US-7696210-B2 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2010-04-13 | — | — | US | disclosed |
| US-20060019965-A1 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019965-A1 | Gonadotropin releasing hormone receptor antagonists | GNRHR, GHRHR, LHCGR | GNRHR 1/4885TACR2 137/4885HRH2 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.